Recombinant Human NOV/CCN3 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human NOV/CCN3 Protein, CF Summary

• Details of Functionality: Measured by its ability to mediate Balb/3T3 mouse embryonic fibroblast cell adhesion. Ball, D.K. et al. (2003) Reproduction 125:271. rhNOV, immobilized at 10 µg/mL, 100 µL/well, will mediate >30% Balbc/3T3 cell adhesion (3 x 10⁴ cells/well added).
• Source: Mouse myeloma cell line, NS0-derived human NOV/CCN3 protein
  Thr32-Met357, with a C-terminal 10-His tag
• Accession #: P48745
• N-terminal Sequence: Thr32
• Protein/Peptide Type: Recombinant Proteins
• Gene: NOV
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 37.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 48-60 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human NOV/CCN3 Protein, CF

• CCN family member 3
• CCN3
• CCN3IGF-binding protein 9
• IBP-9
• IGFBP-9
• IGFBP9novH
• Insulin-like growth factor-binding protein 9
• nephroblastoma overexpressed gene
• Nephroblastoma-overexpressed gene protein homolog
• NOV
• NOVH
• protein NOV homolog

Background

NOV, also called CCN3, is one of six CCN (CYR61/CTGF/NOV) secreted proteins which share a common multimodular organization (1 - 4). NOV/CCN3 contains an N-terminal IGFBP domain that appears to be non-functional and a vWF type C and thrombospondin type I domain which mediate oligomerization and matrix interactions, respectively (1, 2). The C-terminal cysteine knot domain interacts with several partners, including the matrix protein fibulin 1C (5), Notch-1 (6), and CCN2, with which it may heterodimerize (2). NOV/CCN3 also interacts with the gap junction protein Connexin43 and mediates suppression of proliferation (7). It also binds the calcium binding protein S100A4 and promotes calcium channel activation (8). The 357 amino acid (aa), 44 kDa human NOV/CCN3 shares 80% aa identity with mouse, rat and dog NOV/CCN3, and 78% aa identity with cow NOV/CCN3. NOV/CCN3 also shows 38 - 50% aa identity with other family members including WISP proteins, except for WISP-2/CCN5 which lacks the cysteine knot (1). NOV/CCN3 is widely expressed developmentally, especially in muscle, endothelium, nervous system, adrenal cortex and chondrocytes (1 - 4). In transformed cells, a 32 kDa N-terminally truncated form lacks the signal sequence is localized to the nucleus. Truncation allows a C-terminal nuclear localization sequence to be active (9). Nuclear NOV/CCN3 acts as a transcriptional repressor but promotes proliferation, presumably by interfering with growth control (9). Full length NOV/CCN3 is a secreted matricellular protein which inhibits cell growth. Interaction of NOV/CCN3 with integrins alpha _v beta ₃ and  alpha ₅ beta ₁ mediates endothelial cell adhesion, chemotaxis, and promotes angiogenesis (10, 11). Over-expression of NOV/CCN3 downregulates myogenic genes such as MyoD (12).

1. Perbal, B. (2004) Lancet 363:62.
2. Perbal, B. (2006) Cell Commun. Signal. 4:3.
3. Martinerie, C. et al. (1994) Oncogene 9:2729.
4. Snaith, M. R. et al. (1996) Genomics 38:425.
5. Perbal, B. et al. (1999) Proc. Natl. Acad. Sci. USA 96:869.
6. Sakamoto, K. et al. (2002) J. Biol. Chem. 277:29399.
7. Fu, C. T. et al. (2004) J. Biol. Chem. 279:36943.
8. Li, C. L. et al. (2002) Mol. Pathol. 55:250.
9. Planque, N. et al. (2006) J. Cell. Biochem. 99:105.
10. Lin, C. G. et al. (2003) J. Biol. Chem. 278:24200.
11. Lin, C. G. et al. (2003) J. Biol. Chem. 280:8229.
12. Calhabeu, F. et al. (2006) Exp. Cell. Res. 312:1876.

Publications for NOV/CCN3 (1640-NV)(7)

Publications using 1640-NV

• S Son, H Kim, H Lim, JH Lee, KM Lee, I Shin CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer Cell Death & Disease, 2023-02-03;14(2):81. 2023-02-03 [PMID: 36737605] (Bioassay, Human)
• R Gupta, V Turati, D Brian, C Thrussel, B Wilbourn, G May, T Enver Nov/CCN3 Enhances Cord Blood Engraftment by Rapidly Recruiting Latent Human Stem Cell Activity Cell Stem Cell, 2020-03-19;0(0):. 2020-03-19 [PMID: 32197066] (Bioassay, Human)
• AD Kolb, AB Shupp, D Mukhopadhy, FC Marini, KM Bussard Osteoblasts are &quot;educated&quot; by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment Breast Cancer Res., 2019-02-27;21(1):31. 2019-02-27 [PMID: 30813947] (Bioassay, Human)
• van Roeyen CR, Boor P, Borkham-Kamphorst E, Rong S, Kunter U, Martin IV, Kaitovic A, Fleckenstein S, Perbal B, Trautwein C, Weiskirchen R, Ostendorf T, Floege J A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effects. Am. J. Pathol., 2012-05-01;180(5):1979-90. 2012-05-01 [PMID: 22538190] (Bioassay, Human)
• Zhang Y, Wang C Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. Oncogene, 2011-03-21;30(32):3549-62. 2011-03-21 [PMID: 21423212] (Bioassay, Human)
• Sin WC, Tse M, Planque N, Perbal B, Lampe PD, Naus CC Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization. J. Biol. Chem., 2009-08-25;284(43):29935-44. 2009-08-25 [PMID: 19706598] (Bioassay, Human)
• Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am. J. Pathol., 2009-04-09;174(5):1725-34. 2009-04-09 [PMID: 19359517] (ELISA (Standard))

FAQs for NOV/CCN3 (1640-NV). (Showing 1 - 1 of 1 FAQs).

1. I am looking for the expression of CCN3/NOV in tumor cells and I am interested in finding an antibody that has a lot of data to support the antibody is working well. Can you make a recommendation?
   • We have two antibodies, NBP1-88154 and NBP1-88155 that have been extremely well characterized by testing at the Human Protein Atlas. Please see the Human Protein Atlas website for full testing for these products.

Bioinformatics

• Gene Symbol: NOV
• Uniprot:
  • P48745()